Abstract Background: Cancer-testis antigens (CTAs) have restricted expression in normal adult tissues but have been found to be overexpressed in multiple tumors. This and their ability to elicit spontaneous cellular and humoral immune responses have rendered CTAs as...
Abstract Background Cancer testis antigens (CTAs) are tumor antigens that have a highly tissue-restricted expression but are often expressed in diverse malignancies. With their highly immunogenic expression limited to tumor cells, CTAs have become a prime target for...
Last year, the Buffalo-based cancer diagnostics firm @OmniSeq quietly was acquired by one of the world's largest life science companies, @Labcorp . Developing molecular diagnostic tests for cancer patients, OmniSeq is looking to scale its operations.
In case you missed it be sure to check out OmniSeq’s @AACR poster, “Cancer testis antigen burden: Pan-cancer distribution and survival implications”.
@Labcorp @LabcorpDrugDev @OmniSeq
Learn how @OmniSeq is optimizing RNA-seq cutoff values and sensitivity for PD-L1 by RNA-seq in NSCLC in comparison to IHC. @AACR Poster session 31, 4/11/22, 9AM-12:30PM. ”PD-L1 expression by RNA-sequencing and survival from pembrolizumab in non-small cell lung cancer (NSCLC)".
Congrats to everyone at @OmniSeq on this @PLOS ONE publication! Using more than 700 FFPE tumor specimens, OmniSeq validated the performance of the @illumina's TSO500 assay, an integral component OmniSeq INSIGHT https://tinyurl.com/3ummv3dd